Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Neth Heart J ; 28(3): 131-135, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31696408

ABSTRACT

An early invasive strategy in patients who have acute coronary syndrome without ST-elevation (NSTE-ACS) can improve clinical outcome in high-risk subgroups. According to the current guidelines of the European Society of Cardiology (ESC), the majority of NSTE-ACS patients are classified as "high-risk". We propose to prioritise patients with a global registry of acute coronary events (GRACE) risk score >140 over patients with isolated troponin rise or electrocardiographic changes and a GRACE risk score <140. We also acknowledge that same-day transfer for all patients at a high risk is not necessary in the Netherlands since the majority of Dutch cardiology departments are equipped with a catheterisation laboratory where diagnostic coronary angiography is routinely performed in NSTE-ACS patients. Therefore, same-day transfer should be restricted to true high-risk patients (in addition to those NSTE-ACS patients with very high-risk (VHR) criteria) in centres without coronary angiography capabilities.

2.
Neth Heart J ; 27(4): 191-199, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30684141

ABSTRACT

BACKGROUND: European Society of Cardiology (ESC) guidelines recommend same-day transfer to a percutaneous coronary intervention (PCI) centre for angiography in high-risk (ESC-HR) patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). We describe the treatment patterns of NSTE-ACS patients presenting at non-PCI centres and evaluate the logistical consequences of adopting same-day transfer. METHODS: From August 2016 until January 2017, all consecutive NSTE-ACS patients presenting at 23 non-PCI centres in the Netherlands were recorded. We built an online case report form in collaboration with the National Cardiovascular Database Registry to collect information on risk stratification by the attending physician, timing and location of angiography, and treatment. RESULTS: We included 871 patients (mean age 69.1 ± 12.8). 55.8% were considered ESC-HR. Overall, angiography at non-PCI centres was 55.1% and revascularisation was 54.1%. Among ESC-HR patients, angiography at non-PCI centres was 51.4% and revascularisation was 54.9%. Angiography <24 h was 55.6% in patients with angiography at a non-PCI centre and 74.3% in patients with angiography at a PCI-centre. Assuming patients would receive similar treatment, adoption of same-day transfer would increase transfers of ESC-HR patients who undergo PCI (44.3%), but also increases transfers of medically treated patients (36.2%) and patients awaiting coronary bypass artery grafting (9.1%). CONCLUSIONS: In this registry of NSTE-ACS patients at non-PCI centres, the majority of ESC-HR patients underwent angiography at a non-PCI centre. Same-day transfer occurred in one-quarter of the ESC-HR patients, despite guideline recommendation. Nonselective adoption of same-day transfer to a PCI centre would increase transfers of ESC-HR patients who undergo PCI, however, equally increases transfers of patients who are medically treated.

3.
Neth Heart J ; 26(9): 417-421, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29974355

ABSTRACT

On behalf of the Dutch ACS working group, we discuss the most important changes in recommendations in the 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation relevant for both the general and interventional cardiologist.

4.
Neth Heart J ; 25(3): 181-185, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27966184

ABSTRACT

On behalf of the Dutch ACS working group, we discuss multiple recommendations which have been implemented in the 2015 ESC guidelines for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation.

5.
Diabetologia ; 55(8): 2154-62, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22618812

ABSTRACT

AIMS/HYPOTHESIS: The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes. METHODS: In total, 605 patients aged 60 years or over with type 2 diabetes in the south west of the Netherlands participated in this cross-sectional study (response rate 48.7%), including 24 with a cardiologist-confirmed diagnosis of heart failure. Between February 2009 and March 2010, the patients without known heart failure underwent a standardised diagnostic work-up, including medical history, physical examination, ECG and echocardiography. An expert panel used the criteria of the European Society of Cardiology to diagnose heart failure. RESULTS: Of the 581 patients studied, 161 (27.7%; 95% CI 24.1%, 31.4%) were found to have previously unknown heart failure: 28 (4.8%; 95% CI 3.1%, 6.6%) with reduced ejection fraction, and 133 (22.9%; 95% CI 19.5%, 26.3%) with preserved ejection fraction. The prevalence of heart failure increased steeply with age. Heart failure with preserved ejection fraction was more common in women. Left ventricular dysfunction was diagnosed in 150 patients (25.8%; 95% CI 22.3%, 29.4%); 146 (25.1%; 95% CI 21.6%, 28.7%) had diastolic dysfunction. CONCLUSIONS/INTERPRETATION: This is the first epidemiological study that provides exact prevalence estimates of (previously unknown) heart failure and left ventricular dysfunction in a representative sample of patients with type 2 diabetes. Previously unknown heart failure and left ventricular dysfunction are highly prevalent. Physicians should pay special attention to 'unmasking' these patients.


Subject(s)
Diabetes Mellitus, Type 2/epidemiology , Diabetic Angiopathies/epidemiology , Heart Failure/epidemiology , Ventricular Dysfunction, Left/epidemiology , Aged , Aged, 80 and over , Blood Glucose/metabolism , Creatinine/metabolism , Cross-Sectional Studies , Diabetes Mellitus, Type 2/blood , Diabetic Angiopathies/blood , Echocardiography , Female , Glycated Hemoglobin/metabolism , Humans , Male , Mass Screening , Middle Aged , Natriuretic Peptide, Brain/blood , Netherlands/epidemiology , Peptide Fragments/blood , Prevalence , Stroke Volume
6.
Neth Heart J ; 19(2): 61-7, 2011 Feb.
Article in English | MEDLINE | ID: mdl-22020943

ABSTRACT

OBJECTIVE: This study aims to assess the cost-effectiveness of ezetimibe plus simvastatin (E/S) versus atorvastatin or simvastatin monotherapy as second-line treatment of primary hypercholesterolaemia from the Dutch healthcare perspective. METHODS: The evaluation used a Markov model and patient data from the Dutch EASEGO study in which patients failing to reach goal low-density lipoprotein cholesterol levels on atorvastatin 10 mg or simvastatin 20 mg had their dose doubled or switched to ezetimibe 10 mg plus generic simvastatin 20 mg (E10/S20). The second scenario, based on Dutch guidelines, switched patients from simvastatin 40 mg to atorvastatin 40 mg, or ezetimibe 10 mg was added to simvastatin 40 mg (E10/S40). The key effectiveness input measure was change in total cholesterol/high-density lipoprotein ratio obtained from the EASEGO study. In conformity with published studies linking reduced lipid levels to reduced risk of cardiovascular events, the present model assumed that a lipid decrease with ezetimibe may be a signal for reduced risk of cardiovascular events. Model parameters were derived from published literature. Sensitivity analyses were performed for the key parameters. RESULTS: In the EASEGO scenario, incremental cost-effectiveness ratio for E10/S20 was 3497/quality-adjusted life-years (QALY) vs atorvastatin 20 mg and 26,417/QALY vs simvastatin 40 mg. In the Dutch guidelines scenario, E10/S40 was dominant (more effective and cost-saving) vs atorvastatin 40 mg. Varying model inputs had limited impact on the cost-effectiveness of E/S. CONCLUSIONS: The analysis showed the cost-effectiveness of E/S versus atorvastatin 20 mg or simvastatin 40 mg (EASEGO scenario) at a threshold of 30,000/QALY and vs atorvastatin 40 mg was dominant (Dutch guidelines). Thus, E/S seems a valuable cost-effective second-line treatment option for patients not attaining lipid treatment goals.

7.
Atherosclerosis ; 209(1): 189-94, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19818960

ABSTRACT

BACKGROUND: Heterozygous familial hypercholesterolemia (heFH) is a common autosomal dominant hereditary disorder caused by mutations in the LDL-receptor gene that lead to elevated plasma levels of low-density lipoprotein-cholesterol (LDL-c). Robust lowering of LDL-c levels is essential for risk reduction of premature cardiovascular diseases and early death. European and Dutch guidelines recommend to treat LDL-c to plasma levels <2.5mmol/l. In the present study we evaluated the treatment of heFH patients in The Netherlands. METHODS: A cross-sectional study was conducted in outpatient lipid clinics of three Academic Centers and two regional hospitals. Patient records of known heFH patients were retrieved and data were reviewed on the use of lipid-lowering medication, plasma lipids and lipoproteins, safety laboratory results and reasons for not achieving treatment goals. RESULTS: The data of 1249 patients with heFH were available. Nearly all patients (96%) were on statin treatment. The treatment goal for LDL-c <2.5mmol/l was achieved in 261 (21%) patients. Among those who did not reach LDL-c goals, 261 (27%) were on combination therapy of maximum statin dose and ezetimibe. Main reason (32%) why patients did not use maximum therapy despite an LDL-c >or=2.5mmol/l, was acceptance of a higher target LDL-c level by the treating physician. An alternative treatment goal of >50% LDL-c reduction, as recommended in the NICE guidelines, was achieved in 47% of patients with an LDL-c >or=2.5mmol/l and not using maximum therapy. CONCLUSION: Only a small proportion of patients with heFH reaches the LDL-c treatment target of <2.5mmol/l. These results emphasize the need for better monitoring, better utilization of available medication and for new treatment options in heFH to further decrease LDL-c levels.


Subject(s)
Azetidines/therapeutic use , Cardiovascular Diseases/prevention & control , Cholesterol, LDL/blood , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipoproteinemia Type II/drug therapy , Adult , Aged , Cardiovascular Diseases/etiology , Cross-Sectional Studies , Drug Monitoring , Ezetimibe , Female , Humans , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/complications , Male , Middle Aged , Netherlands
8.
Neth Heart J ; 17(9): 322-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19949473

ABSTRACT

Background. Patients with coronary artery disease are at high risk of coronary events and death, but effective secondary prevention can reduce this risk. There is a gap between guidelines on secondary prevention and the implementation of these measures, which could potentially be reduced by nurse led prevention clinics (NLPC).Objectives. The aim of the current study is to quantify the impact of NLPC on the risk of cardiovascular events in patients with established coronary artery disease.Methods. A randomised, multicentre clinical trial of NLPC in addition to usual care or usual care alone in post-acute coronary syndrome patients. (Neth Heart J 2009;17:322-8.).

9.
Curr Med Res Opin ; 24(4): 1065-8, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18312742

ABSTRACT

OBJECTIVE: All factors of the metabolic syndrome (MetS) are reported to be associated with elevated C-reactive protein (CRP) levels. As CRP levels have been found to decrease as a result of statin treatment, the present study was intended to explore the relationship between CRP and the MetS in statin treated patients. METHODS: In this study, the relationship between the components of the MetS and CRP level were analysed and factors determining CRP were identified in patients with longstanding intensive lipid lowering therapy with known cardiovascular disease. RESULTS: In this population CRP levels are still associated with the MetS, with waist circumference, fasting glucose level and smoking being the most important determinants of CRP levels. CONCLUSIONS: CRP levels are still associated with the MetS in patients treated with intensive lipid lowering therapy.


Subject(s)
C-Reactive Protein/drug effects , C-Reactive Protein/metabolism , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypolipidemic Agents/therapeutic use , Metabolic Syndrome/blood , Atorvastatin , Blood Pressure , Enzyme Inhibitors/therapeutic use , Female , Fluorobenzenes/therapeutic use , Heptanoic Acids/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hypolipidemic Agents/pharmacology , Logistic Models , Male , Metabolic Syndrome/physiopathology , Middle Aged , Pilot Projects , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Risk Factors , Rosuvastatin Calcium , Simvastatin/therapeutic use , Smoking , Sulfonamides/therapeutic use
10.
Curr Med Res Opin ; 24(2): 359-64, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18081989

ABSTRACT

BACKGROUND: It is generally accepted that low density lipoprotein cholesterol (LDL-C) or calculated ratios such as LDL-C to high density lipoprotein cholesterol (HDL-C) (LDL-C/HDL-C) are useful predictors of risk of cardiovascular disease in the primary as well as in the secondary prevention setting. However, there is accumulating evidence that the ratio of the corresponding apolipoproteins (apoB/A1) might be superior in some populations. Little is known with regard to the prognostic significance of apoB/A1 in patients treated with statins according to the guidelines. OBJECTIVE: The present study assesses the prognostic value of apoB/A1 in such patients receiving statin therapy. METHODS: This study was performed in a population of 593 statin-treated patients with known coronary heart disease (CHD). It is a post-hoc analysis of a published study on the effect of folic acid on cardiovascular risk. The association of lipids and apolipoproteins with cardiovascular events was evaluated using univariate and multivariate Cox regression models. RESULTS: The apoB/A1 ratio was associated with clinical outcome when corrected for standard risk factors, whereas LDL-C/HDL-C was not, which could indicate additional significant prognostic value of apoB/A1 over and above this classic lipid ratio. However, this additional prognostic value was not confirmed by receiver operating characteristic (ROC) curves, which showed no increase in the area under the curve. CONCLUSION: In statin-treated patients with known CHD, apoB/A1 is positively associated with clinical events, whereas the LDL-C/HDL-C is not, but apoB/A1 does not increase the area under the curve.


Subject(s)
Apolipoprotein A-I/blood , Apolipoproteins B/blood , Cardiovascular Diseases/prevention & control , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Treatment Outcome , Aged , Biomarkers , Cholesterol, HDL/drug effects , Cholesterol, LDL/drug effects , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Male , Prognosis , Risk Factors
11.
Ned Tijdschr Geneeskd ; 151(26): 1469-73, 2007 Jun 30.
Article in Dutch | MEDLINE | ID: mdl-17633978

ABSTRACT

A 53-year-old man and a 76-year-old woman were treated with the cytotoxic drug capecitabine as palliative treatment and adjuvant treatment, respectively, because of colorectal carcinoma. Both developed myocardial ischaemia within a few days. In the man, the capecitabine dosage was reduced and metoprolol was prescribed, while in the woman the capecitabine was stopped. According to the literature, the risk of myocardial ischaemia during treatment with capecitabine is approximately 0.4%, irrespective of the patient's medical history. Except in clinical trials, a history of coronary disease is not considered a contraindication for capecitabine treatment. In case stable angina pectoris develops during treatment, continuation of treatment with a reduced dosage of capecitabine can be considered. A switch to treatment with an alternative fluoropyrimidine, such as fluorouracil or raltitrexed, also appears to be safe. However, raltitrexed is no longer available in The Netherlands.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Deoxycytidine/analogs & derivatives , Fluorouracil/analogs & derivatives , Myocardial Ischemia/chemically induced , Aged , Antimetabolites, Antineoplastic/therapeutic use , Capecitabine , Colorectal Neoplasms/drug therapy , Deoxycytidine/adverse effects , Deoxycytidine/therapeutic use , Female , Fluorouracil/adverse effects , Fluorouracil/therapeutic use , Humans , Male , Middle Aged
12.
J Intern Med ; 256(6): 482-90, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15554949

ABSTRACT

OBJECTIVE: To determine the contribution of classical risk factors to the development of cardiovascular disease (CVD) in patients with heterozygous familial hypercholesterolaemia (FH). DESIGN: A retrospective, multi-centre, cohort study. Extensive data were collected by scrutinizing medical records and the use of questionnaires. Multivariate Cox regression was used to study the relationship between potential risk factors and the occurrence of CVD. SETTING AND SUBJECTS: We included 2400 FH patients from 27 Dutch lipid clinics. The diagnosis of FH was based upon the presence of a low-density lipoprotein receptor mutation or upon strict clinical criteria. MAIN OUTCOME MEASURES: Cardiovascular mortality and CVD. RESULTS: During 112.943 person-years, 782 (32.6%) patients had had at least one cardiovascular event. Male gender (RR 2.82, 95% CI 2.37-3.36), smoking (RR 1.67, 95% CI 1.40-1.99), hypertension (RR 1.36, 95% CI 1.06-1.75), diabetes mellitus (RR 2.19, 95% CI 1.36-3.54), low HDL-C (RR 1.37, 95% CI 1.15-1.63) and elevated lipoprotein(a) levels (RR 1.50, 95% CI 1.20-1.79) proved to be independent CVD risk factors. These six risk factors explained 18.7% of the variation in the occurrence of CVD. CONCLUSIONS: Male gender, smoking, hypertension, diabetes mellitus, HDL cholesterol and lipoprotein(a) levels proved to be important risk factors for CVD in FH patients. In addition to the routine institution of statin therapy, controlling these factors needs special attention in the management of this disorder.


Subject(s)
Cardiovascular Diseases/etiology , Hyperlipoproteinemia Type II/complications , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/genetics , Cardiovascular Diseases/mortality , Cholesterol, HDL/blood , Diabetic Angiopathies/etiology , Diabetic Angiopathies/genetics , Diabetic Angiopathies/mortality , Female , Heterozygote , Humans , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/genetics , Hypertension/complications , Lipoprotein(a)/blood , Male , Middle Aged , Retrospective Studies , Risk Factors , Sex Factors , Smoking/adverse effects , Survival Analysis
13.
Int J Cardiol ; 93(2-3): 175-9, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14975544

ABSTRACT

BACKGROUND: Folic acid is assumed to have favourable effects on vascular endothelium, directly as well as indirectly through its effect on homocysteine metabolism. However, the clinical value of folic acid in secondary prevention after acute myocardial infarction (MI) has never been tested. Thus, a randomised, open-label, multicentre trial was performed in order to study the effect of folic acid 5 mg o.d. when added to statin therapy on the incidence of recurrent major clinical events up to 1 year post-MI. METHODS: A total of 283 patients with a total cholesterol >6.5 mmol/l (251 mg/dl) (mean 7.3 mmol/l) were included. All patients received 40 fluvastatin. In 140 of the 283 patients, folic acid (5 mg o.d.) was instituted at discharge, and the remaining 143 patients served as controls. Other secondary prevention measures for both groups were advocated. The primary endpoint was a composite consisting of all vascular events, including death, recurrent MI, strokes, and unplanned invasive coronary interventions. RESULTS: At baseline, the two groups were well-matched for all clinical and demographic parameters. After 1 year of treatment, no difference was noticed in the primary endpoint between the two groups. These endpoints occurred in 43 patients (31%) in the folic acid group, as opposed to 45 patients (31%) in the control group. All separate cardiovascular events were also equally distributed between both groups. Total cholesterol levels decreased to a similar extent in the two groups (to 5.5 and 5.7 mmol/l, in folic acid and control groups, respectively). CONCLUSIONS: In this medium-size pilot study, folic acid did not demonstrate any beneficial additive effects on cardiovascular mortality or morbidity in post-MI patients with hypercholesterolemia who were treated with statin therapy. Larger trials, possibly targeting at selected populations, must be awaited before definitive conclusions regarding the potentially favourable effects of folic acid supplementation in secondary prevention can be drawn.


Subject(s)
Anticholesteremic Agents/therapeutic use , Fatty Acids, Monounsaturated/therapeutic use , Folic Acid/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypercholesterolemia/drug therapy , Indoles/therapeutic use , Myocardial Infarction/complications , Anticholesteremic Agents/administration & dosage , Cholesterol/blood , Drug Therapy, Combination , Fatty Acids, Monounsaturated/administration & dosage , Female , Fluvastatin , Folic Acid/administration & dosage , Follow-Up Studies , Humans , Hypercholesterolemia/etiology , Indoles/administration & dosage , Male , Middle Aged , Pilot Projects , Recurrence , Time Factors
14.
Neth Heart J ; 12(11): 491-496, 2004 Nov.
Article in English | MEDLINE | ID: mdl-25696274

ABSTRACT

High-density lipoprotein cholesterol (HDL-c) plays a crucial role in the concept of reverse cholesterol transport and has many other beneficial properties which may interfere with atherogenesis and plaque rupture. Low HDL-c levels are currently considered to be an important risk factor for the development of cardiovascular disease. However until recently no effective and safe treatment for powerfully increasing HDL-c selectively was available. This short overview describes possible new therapeutic approaches that may be able to raise HDL-c levels or improve HDL-c metabolism/reverse cholesterol transport. Today, the most important targets to be evaluated are inhibition of cholesteryl ester transfer protein (CETP) and increasing the HDL-c level by infusion of engineered HDL particles. Trials to prove clinical benefit of new HDL-c raising approaches are underway and may well be a new starting point for an optimised prevention and treatment of atherosclerotic cardiovascular disease.

15.
Int J Cardiol ; 90(1): 15-21, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12821213

ABSTRACT

Low levels of high-density lipoprotein cholesterol (HDL-C) are frequently encountered in patients with coronary artery disease (CAD), most often in combination with elevated triglycerides as part of a dysmetabolic syndrome. Although no large secondary prevention trials with statin therapy with special emphasis on low HDL-C have been performed, some guidance can be extracted from a number of post-hoc analyses on how to treat patients with low levels of HDL-C. In terms of risk reduction, statin therapy appears to be at least as effective in patients with low compared to normal HDL-C levels. Fibrate therapy seems only effective when low HDL-C coincides with a level of low-density lipoprotein cholesterol (LDL-C) in the low-normal range. Before considering combination therapy of statins with fibrates, much emphasis should be put on dietary changes, weight reduction, smoking cessation and regular exercise, since these measures are effective tools to raise HDL-C levels. Moreover, one should be aware of the fact that combination therapy of statins and fibrates is not evidence-based and confers some potential risk of myopathy. Future therapy options may include CETP (cholesterol ester transfer protein) inhibitors, but these agents are still in an experimental phase. As most patients with low HDL-C levels share features of the dysmetabolic syndrome, one could also consider a combination therapy of statins and ACE-inhibitors, since this combination is not only safe, but the individual preventive effects of these compounds appear to be cumulative.


Subject(s)
Coronary Disease/blood , Coronary Disease/prevention & control , Hypolipoproteinemias/therapy , Lipoproteins, HDL/blood , Coronary Disease/etiology , Humans , Hypolipoproteinemias/blood , Hypolipoproteinemias/complications
16.
Eur Heart J ; 23(24): 1931-7, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12473255

ABSTRACT

AIMS: Residual ischaemia following acute myocardial infarction (AMI) is related to an adverse outcome, although the effect of early initiation of statin therapy is unknown. METHODS: A randomized, placebo-controlled, double-blind, parallel study was performed, which compared fluvastatin 80 mg daily with placebo in patients with an AMI and total cholesterol of <6.5 mmol.l(-1). Ischaemia was measured by ambulatory electrocardiographic (AECG) monitoring over 48-h at baseline, after 6 weeks and at 12 months. RESULTS: Five hundred and forty patients were included (83% male, age 61+/-11 years); 43% had an anterior AMI and 50% were treated with fibrinolytics in the acute phase. After 12 months, the total cholesterol (TC) level was reduced by 13% and LDL-C (low-density-lipoprotein cholesterol) by 21% (from 3.5 mmol.l(-1) to 2.7 mmol.l(-1)) in the fluvastatin treatment group. Both TC and LDL increased by 9% in the placebo group (P<0.001 between groups). At baseline, ischaemia on AECG was present in only 11% of patients, and absent in 77%; in the remaining 11%, recordings were technically inadequate. After 6 weeks, 32/48 (67%), and 12 months 35/46 (76%) of the patients with ischaemia on the baseline AECG, no longer showed signs of ischaemia. Nevertheless, ischaemia at baseline was predictive for the occurrence of any major clinical event (RR=2.35; 95% CI 1.39-3.2;P <0.001). Fluvastatin treatment did not affect ischaemia on AECG, nor the occurrence of any major clinical events as compared to placebo. Post-hoc analysis in patients with the most pronounced ischaemia at baseline showed a trend for a beneficial effect of fluvastatin on major clinical events (P=0.084). CONCLUSION: Residual ischaemia after AMI is observed less frequently in the present study, than in earlier studies, although it is predictive for future cardiovascular events. As a result, the present study was underpowered, and no effect of fluvastatin on AECG ischaemia, or major clinical events in the first year after AMI, could be detected. The present data do not confirm other reports which support widespread use of statin treatment early after AMI.


Subject(s)
Fatty Acids, Monounsaturated/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Indoles/therapeutic use , Myocardial Infarction/complications , Myocardial Ischemia/drug therapy , Adult , Aged , Aged, 80 and over , Cholesterol, LDL/blood , Double-Blind Method , Electrocardiography, Ambulatory , Female , Fluvastatin , Humans , Male , Middle Aged , Myocardial Infarction/blood , Myocardial Ischemia/blood
17.
Neth Heart J ; 10(3): 109-110, 2002 Mar.
Article in English | MEDLINE | ID: mdl-25696075
18.
Arterioscler Thromb Vasc Biol ; 18(7): 1101-7, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9672070

ABSTRACT

The association between plasma apolipoprotein (apo) B concentrations and angiographically determined coronary artery disease (CAD) was investigated in women in a cross-sectional study. Stenosis of >60% in 1 or more coronary arteries was classified as CAD+. CAD- was defined as a maximum stenosis of 10% in any coronary artery. Fasting plasma concentrations of apoB, apoA-I, cholesterol (chol), low density lipoprotein cholesterol (LDL-chol), high density lipoprotein cholesterol (HDL-chol), and triglycerides (TGs) were determined. Information on nonlipid risk factors was obtained from questionnaires. CAD+ women (n=160) were older than CAD- women (n=129), 64.0+/-7.8 vs 57.8+/-11.1 years, respectively. CAD+ compared with CAD- women had higher frequencies of diabetes (14.7% vs 5.8%, P=0.05), hypertension (53% vs 37%, P=0.018), and ever-smoking (48% vs 35%, P<0.001). CAD+ women had higher plasma concentrations of apoB (1.48+/-0.32 vs 1.25+/-0.34 g/L, P<0.001), chol (7.01+/-1.19 vs 6.38+/-1.22 mmol/L, P=0.001), LDL-chol (4.74+/-1.09 vs 4.13+/-1.13 mmol/L, P<0.001), and TGs (1.98+/-0.84 vs 1.71+/-0.93 mmol/L, P=0.007) and lower levels of HDL-chol (1.28+/-0.28 vs 1.37+/-1.38 mmol/L, P=0.028). After correction for nonlipid risk factors, apoB, chol, LDL-chol, HDL-chol, and TG were independently related to CAD. In the lowest quartiles of chol, LDL-chol, and TG, CAD+ women had higher apoB concentrations than CAD- women. In contrast, chol, LDL-chol, TG, or HDL-chol levels were not different in any quartile of apoB. ApoB showed the most significant relation with the number of stenotic vessels, and apoB was associated with CAD in the normolipidemic subgroup. In conclusion, apoB was superior to chol, LDL-chol, HDL-chol, TG, and apoA-I in discriminating between CAD+ and CAD-.


Subject(s)
Apolipoproteins B/blood , Coronary Angiography , Coronary Disease/blood , Aged , Apolipoprotein A-I/metabolism , Cholesterol/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cross-Sectional Studies , Female , Humans , Middle Aged , Postmenopause , Risk Factors , Triglycerides/blood
19.
Eur Heart J ; 18(11): 1755-64, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9402450

ABSTRACT

AIMS: The study aimed to compare the addition of felodipine to metoprolol, and of the replacement of metoprolol by felodipine, with continuation of metoprolol, in patients with angina pectoris despite optimal beta-blockade. METHODS AND RESULTS: The study was double-blind, parallel, randomized and controlled, and comprised 363 patients from 27 outpatient cardiology clinics in the Netherlands. The patients had angina and positive bicycle exercise tests despite optimal beta-blockade (resting heart rate < 65 beats.min-1). Randomization was to three treatment groups: continuation of metoprolol (control), addition of felodipine to metoprolol, and replacement of metoprolol by felodipine. Exercise tests were repeated after 2 and 5 weeks. The main outcome measure was: exercise result after 5 weeks, compared with baseline, between-group comparison of changes vs control. There were no significant differences in exercise duration and onset of chest pain vs control. The addition of felodipine increased time until 1 mm ST depression (43 s, 95% confidence interval 20-65 s), and decreased both ST depression at highest comparable work load (0.46 mm, 95% confidence interval 0.19-0.72), and maximal ST depression (0.49 mm, 95% confidence interval 0.23-0.74). Exercise results after replacement of metoprolol by felodipine were not different from control, apart from a significant increase in rate pressure product. Significantly more patients experienced adverse events in the felodipine monotherapy group. CONCLUSION: Combination of metoprolol and felodipine is to be preferred to felodipine monotherapy in patients who have signs and symptoms of myocardial ischaemia despite optimal beta-blockade.


Subject(s)
Adrenergic beta-Antagonists/administration & dosage , Angina Pectoris/drug therapy , Calcium Channel Blockers/administration & dosage , Felodipine/administration & dosage , Metoprolol/administration & dosage , Adolescent , Adult , Aged , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Electrocardiography , Exercise Test , Female , Humans , Male , Middle Aged
20.
Am Heart J ; 107(2): 248-60, 1984 Feb.
Article in English | MEDLINE | ID: mdl-6695659

ABSTRACT

A method is presented for routine estimation of ultimate infarct size in patients with acute myocardial infarction (AMI). This method implies the calculation of the total quantity of alpha-hydroxybutyrate dehydrogenase (HBDH) released by the heart per liter of plasma, with the use of five to seven plasma samples per patient during the first 4 days after onset of infarction. The choice of HBDH for this purpose was motivated by a relatively small error in estimated enzyme release for slowly eliminated enzymes. The practicality of this method was studied in the coronary care unit at Leiden University Hospital where, in 1979, 146 patients with AMI were included in the study. In 100 patients (68%) HBDH-infarct size could be calculated precisely, and in 12 other patients (8%) the assessment of HBDH-infarct size was less accurate. In 34 patients (23%), HBDH-infarct size was unobtainable because of early death (eight cases), infarctions too small in size to assess or nonexistent (six cases), too much time elapsed since infarction (six cases), and incomplete plasma sampling (14 cases). Analysis of data shows that the larger HBDH-infarct sizes were found to be associated significantly with signs of heart failure, low stroke index and low ejection fraction, presence of tachycardias and interventricular conduction disturbances, high score of left ventricular wall motion abnormalities, large myocardial perfusion defect measured with thallium-201, in-hospital death, and death in the first year after infarction. A low but significant correlation was observed between HBDH-infarct size and the severity of coronary arterial lesions.


Subject(s)
Clinical Enzyme Tests/methods , Hydroxybutyrate Dehydrogenase/blood , Myocardial Infarction/diagnosis , Myocardium/enzymology , Cardiac Catheterization , Electrocardiography , Heart/diagnostic imaging , Humans , Mathematics , Prognosis , Radionuclide Imaging , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...